These data are being presented at the Congress of Clinical Rheumatology - West (CCR-West) in Huntington Beach, California, taking place September 17-20, 2026.

Among patients who entered the OLE, Sotyktu demonstrated durable efficacy, with clinical responses continuing to improve from Week 16 through Week 52 and maintained through Week 104. Responses were robust across key clinical efficacy measures, including American College of Rheumatology (ACR) 20/50/70 and Minimal Disease Activity (MDA), both for patients who received Sotyktu continuously from the start of the Phase 3 study through the OLE and patients who switched from placebo to Sotyktu at Week 16 and continued Sotyktu through the remainder of the Phase 3 study and OLE.

Among patients who received Sotyktu continuously from the beginning of the Phase 3 study through the OLE, ACR 20/50/70 response rates at Week 104 were 76.2%, 52.6% and 34.6%, respectively, based on observed analysis, and 65.3%, 44.9% and 29.4%, respectively, using nonresponder imputation (NRI). MDA response rates were 51.2% (observed) and 43.7% (NRI).

Additionally, among patients who switched from placebo to Sotyktu at Week 16 and continued treatment through the OLE, ACR 20/50/70 response rates at Week 104 were 76.9%, 54.6% and 37.7% (observed), and 69.3%, 49.2% and 33.9% (NRI), respectively. MDA response rates for those who switched to Sotyktu were 48.7% (observed) and 43.7% (NRI).

"Psoriatic arthritis is a complex, chronic and often debilitating disease that can affect any part of the body, leaving patients in need of treatment options that can support symptom control beyond the initial months of therapy," said Philip Mease, MD, director of rheumatology research at Providence Swedish Medical Center and clinical professor at the University of Washington School of Medicine, Seattle. "These longer-term results strengthen the evidence supporting Sotyktu as a durable oral option for managing key joint and skin manifestations, with a favorable safety profile."

Results also showed that Sotyktu was well-tolerated through Week 104. Safety outcomes were consistent with the previously reported PsA-2 study results through 52 weeks and with the established long-term Sotyktu safety profile observed in the five-year psoriasis clinical program, with no new safety signals identified. In patients with any Sotyktu exposure through the two-year cumulative period, adverse events (AEs) occurred in 86.6% of 604 patients, serious AEs in 12.6% of patients and AEs leading to discontinuation in 7.6% of patients. The most common AEs were upper respiratory tract infection, nasopharyngitis and COVID-19.

"Following the approval of Sotyktu for adults with active psoriatic arthritis earlier this year, these results through two years of treatment in POETYK PsA-2 reinforce the durable efficacy and safety profile observed across our clinical program and the various subgroups assessed," said Liz Colston, MD, PhD, vice president and head of Immunology development, Bristol Myers Squibb. "These positive data add to our understanding of Sotyktu in psoriatic arthritis and reinforce our confidence in its potential role in helping address the needs of people living with chronic rheumatic diseases."

Bristol Myers Squibb thanks the patients, investigators and clinical trial sites participating in the OLE of the POETYK PsA-2 study. Results from the OLE of the POETYK PsA-1 study will also be presented at an upcoming medical meeting.